Drug intelligence / Profile preview

ABY-251

Development stage: Preclinical
Lead developer: Affibody
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

ABY-251 is a HER2-targeting Affibody molecule being developed as a therapeutic radiopharmaceutical for the treatment of HER2-positive solid tumors. It is a small, 7 kDa structured protein scaffold that binds to the Human Epidermal Growth Factor Receptor 2 (HER2) with high affinity (KD = 100pM). ABY-251 is designed to be labeled with rhenium-188 (188Re), a beta-emitting radionuclide, to deliver targeted radiotherapy directly to HER2-expressing tumors. It is intended for use in a theranostic approach, where patients are first screened with the diagnostic imaging agent ABY-025 to confirm HER2 expression before receiving ABY-251 therapy. Potential indications include metastatic breast cancer, non-small cell lung cancer, and gastroesophageal junction cancer.

Other names: ABY-251-Affibody-HER2-Affibody moleculeABY251-Affibody-HER2-Affibody moleculeABY 251-Affibody-HER2-Affibody molecule

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on ABY-251.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABY-251.

Explore the full profile